IPO
Recent changes
- Aug 7, 2026Aug 7, 2026IPO $150M BioSpace
Funding History
1 event · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Aug 7, 2026 | ipo | $150M | — | Pulse story |
Latest Pulse
- Aug 7, 2026BlossomHill Prices Upsized $150M IPO, Debuts on NasdaqBlossomHill Therapeutics priced an upsized IPO at $16 a share for $150M and began trading on Nasdaq under BLSM, more than 50% above the $100M target Pulse flagged when the company first filed.→
- Aug 3, 2026BlossomHill Files for $100M Nasdaq IPO in Cancer DrugsBlossomHill Therapeutics filed for a $100M Nasdaq IPO under ticker BLSM, adding an oncology-focused biotech with $257M in prior funding to a summer pipeline of clinical-stage listings led by J.P. Morgan, Leerink and Guggenheim.→
Coverage Timeline
newest firstAll Coverage
IPO$150M IPO
BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq
BlossomHill Therapeutics priced an upsized IPO at $16 a share for $150M and began trading on Nasdaq under BLSM, more than 50% above the $100M target Pulse flagged when the company first filed.
FOLLOW-UP
IPO
BlossomHill Files for $100M Nasdaq IPO in Cancer Drugs
IPO$100M IPO target
BlossomHill Files for $100M Nasdaq IPO in Cancer Drugs
BlossomHill Therapeutics filed for a $100M Nasdaq IPO under ticker BLSM, adding an oncology-focused biotech with $257M in prior funding to a summer pipeline of clinical-stage listings led by J.P. Morgan, Leerink and Guggenheim.
Related Companies
Sources & methodologyshow
Where these figures come from
- BioSpaceValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.